Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Ruxolitinib for the Treatment of Immune-related Vitiligo-like Depigmentation: A Prospective, Multicentre Study of a Topical JAK-inhibitor

NCT07725432 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT07725432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07725432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Ruxolitinib for the Treatment of Immune-related Vitiligo-like Depigmentation: A Prospective, Multicentre Study of a Topical JAK-inhibitor
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 25, 2024
Completion date
August 31, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-related vitiligo-like-depigmentation